Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK)

Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK)

<p dir="ltr">The evidence of rivaroxaban's pharmacokinetics in obese compared with non‐obese populations remains inconclusive. We aimed to compare the pharmacokinetic profile of rivaroxaban between obese and non‐obese populations under fed state. Participants who met the study&#...

Full description

Saved in:
Bibliographic Details
Main Author: Majdoleen Alalawneh (13961580) (author)
Other Authors: Ahmed Awaisu (5121473) (author), Ibtihal Abdallah (14151597) (author), Hazem Elewa (3592601) (author), Mohammed Danjuma (9960506) (author), Kamal M. Matar (14504790) (author), Akram M. ElKashlan (22045142) (author), Yasser Elshayep (22045145) (author), Fathy Ibrahim (22045148) (author), Ousama Rachid (14158917) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Medical biochemistry and metabolomics
Nutrition and dietetics
Pharmacology and pharmaceutical sciences
Rivaroxaban
Pharmacokinetics
Obesity
Body mass index (BMI)
Anticoagulants
Drug metabolism
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items